New anticonvulsants: A review of applications for the management of substance abuse disorders

Annals of Clinical Psychiatry

Volumn 14, Issue 4, 2002, Pages 233-245

  Gentry, John R ^a,b   Hill, Caroline ^a   Malcolm, Robert ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Gabapentin; Oxcarbazepine; Pharmacotherapy; Substance abuse; Tiagabine

Indexed keywords

1 [2 (BENZHYDRYLIDENEAMINOOXY)ETHYL] 1,2,5,6 TETRAHYDRO 3 PYRIDINECARBOXYLIC ACID; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; ALCOHOL; ANTACID AGENT; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CIMETIDINE; CLOMETHIAZOLE; COCAINE; CYTOCHROME P450; DIAZEPAM; ERYTHROMYCIN; ETHINYLESTRADIOL; GABAPENTIN; HALOPERIDOL; LEVONORGESTREL; LIVER ENZYME; LORAZEPAM; NEUROTRANSMITTER; ORAL CONTRACEPTIVE AGENT; OXAZEPAM; OXCARBAZEPINE; PLASMA PROTEIN; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VERAPAMIL;

ALCOHOL WITHDRAWAL; ATAXIA; CLINICAL TRIAL; COCAINE DEPENDENCE; DRUG MECHANISM; DRUG METABOLISM; EPILEPSY; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPONATREMIA; INSOMNIA; NEUROTOXICITY; NONHUMAN; NYSTAGMUS; PRIORITY JOURNAL; RELAPSE; REVIEW; SEIZURE; SLEEP DISORDER; SOCIAL PHOBIA; SOMNOLENCE; SUBSTANCE ABUSE; VERTIGO; WITHDRAWAL SYNDROME;

ANTICONVULSANTS; CLINICAL TRIALS; DRUG INTERACTIONS; FOLLOW-UP STUDIES; HUMANS; METABOLIC CLEARANCE RATE; RECURRENCE; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 0037003914     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021921118070     Document Type: Review

References (98)

1. Hobbs WR, Rall TW, Verdoorn TA: Hypnotics and sedatives: Ethanol. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn. New York: McGraw-Hill; 1996
2. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L: A summary of mechanistic hypothesis of gabapentin pharmacology. Epilepsy Res 1998; 29:233-249
3. Myrick H, Henderson S, Brady K, Malcolm R: Gabapentin in the treatment of cocaine dependence: A case series. J Clin Psychiatry 2001; 62:19-23
4. Magnus L: Nonepileptic uses of gabapentin. Epilepsia 1999; 40(Suppl 6):S66-S72
5. Sabers A, Gram L: Newer anticonvulsants: Comparative review of drug interactions adverse effects. Drugs 2000; 60:23-33
6. Willmore LJ: Choice and use of newer anticonvulsant drugs in older patients. Drugs Aging 2000; 17:441-452
7. Anonymous: Physicians Desk Reference 2002. Montvale: Medical Economics Company; 2002
8. Bonnet U, Banger M, Leweke FM, Maschke M, Kowalski T, Gastpar M: Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry 1999; 32:107-109
9. Watson WP, Robinson E, Little HJ: The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome. Neuropharmacology 1997; 36:1369-1375
10. Bailey CP, Molleman A, Little HJ: Comparison of the effects of drugs on hyperexcitability induced in hippocampal slices by withdrawal from chronic ethanol consumption. Br J Pharmacol 1998; 123:215-222
11. Malcolm R, Myrick H, Brady K, Ballenger J: Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Addict 2001; 10(Suppl):16-23
12. Myrick H, Malcolm R, Brady K: Gabapentin treatment of alcohol withdrawal. Am J Psychiatry 1998; 155:1626
13. Jefferson JM: Benzodiazepines and anticonvulsants for the social phobia (social anxiety disorder). J Clin Psychiatry 2001; 62(Suppl 1):50-53
14. Van Ameringen M, Mancini C: Pharmacotherapy of social anxiety disorder at the turn of the millenium. Psychiatr Clin North Am 2001; 24:783-803
15. Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM: Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol 1999; 19:341-348
16. Blanco C, Antia SX, Liebowitz MR: Pharmacotherapy of social anxiety disorder. Biol Psychiatry 2002; 51:109-120
17. Chatterjee C, Ringold A: A case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin. J Clin Psychiatry 1999; 60:617
18. Hamner MB, Brodrick PS, Labbate LA: Gabapentin in PTSD: A retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001; 13:141-146
19. Vieta E, Martinez-Aran A, Nieto E, Colom F, Reinares M, Benabarre A, Gasto C: Adjunctive gabapentin treatment of bipolar disorder. Eur Psychiatry 2000; 15:433-437
20. Yasmin S, Carpenter LL, Leon Z, Siniscalchi JM, Price LH: Adjunctive gabapentin in treatment-resistant depression: A retrospective chart review. J Affect Disord 2001; 63:243-247
21. Karam-Hage M, Brower K: Gabapentin treatment for insomnia associated with alcohol dependence. Am J Psychiatry 2000; 157:151
22. Withers NW, Pulvirenti L, Koob GF, Gillin JC: Cocaine abuse and dependence. J Clin Psychopharmacol 1995; 15:63-78
23. Raby WN: Gabapentin therapy for cocaine cravings. Am J Psychiatry 2000; 157:12
24. Markowitz J, Finkenbine R, Myrick H: Gabapentin abuse in a cocaine user: Implications for treatment. J Clin Psychopharmacol 1997; 17:423-424
25. de-Paris F, Brusnello JV, Vianna MR, Salgueiro JB, Quevedo J, Izquierdo I, Kapczinski F: The anticonvulsant compound gabapentin posses anxiolytic but not amnestic effects in rats. Behav Pharmacol 2000; 11:169-173
26. Gasior M, Ungard J, Witkin J: Preclinical evaluation of newly approved and potential antiepileptic drugs against cocaine-induced seizures. J Pharmacol Exp Ther 1999; 290:1148-1156
27. Lado FA, Sperber EF, Moshe SL: Anticonvulsant efficacy of gabapentin on kindling in the immature brain. Epilepsia 2001; 42:458-463
28. Dam M, Ekberg R, Løyning Y, Waltimo O, Jakobsen K: A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3:70-76
29. Reinikainen KJ, Keränen T, Halonen T, Komulainen H, Riekkinen PJ: Comparison of oxcarbazepine and carbamazepine: A double-blind study. Epilepsy Res 1987; 1:284-289
30. Wamil AW, Portet Ch, Jensen PK, Schmutz M, McLean MJ: Oxcarbazepine and its monohydroxy metabolite limit action potential firing by mouse central neurons in cell culture. Epilepsia 1991; 32(Suppl 3):65-66
31. Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HR: Oxcarbazepine: Preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia 1994; 35(Suppl 5):S47-S50
32. Faigle JW, Menge GP: Pharmacokinetic and metabolic features of oxcarbazepine and their clinical significance: Comparison with carbamazepine. Int Clin Psychopharmacol 1990; 5:73-82
33. Klitgaard NA, Kristensen O: Use of saliva for monitoring oxcarbazepine therapy in epileptic patients. Eur J Clin Pharmacol 1986; 31:91-94
34. Patsalos PN, Elyas AA, Zakrzewska JM: Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia. Eur J Clin Pharmacol 1990; 39:413-455
35. Degen PH, Flesch G, Cardot JM, Czendlik C, Dieterle W: The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. Biopharm Drug Dispos 1994; 15:519-526
36. Larkin JG, McKee PJW, Forrest G, Beastall GH, Park BK, Lowrie JI, Lloyd P, Brodie MJ: Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol 1991; 31:65-71
37. Rouan MC, Lecaillon JB, Godbillon J, Menard F, Darragon T, Meyer P, Kourilsky O, Hillion D, Aldigier JC, Jungers P: The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Pharmacol 1994; 47:161-167
38. van Heiningen PNM, Eve MD, Oosterhuis B, Jonkman JHG, de Bruin H, Hulsman JARJ, Richens S, Klosterskov Jensen P: The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991; 4:410-419
39. Keränen T, Jolkkonen J, Jensen PK, Menge GP, Andersson P: Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand 1992; 86:120-123
40. Keranen T, Jolkkonen J, Klosterskov-Jensen P, Menge GP: Oxcarbazepine does not interact with cimetidine in healthy volunteers. Acta Neurol Scand 1992; 85:239-242
41. Sonnen AEH: Oxcarbazepine and oral contraceptives. Acta Neurol Scand 82(Suppl 133):37
42. Krämer G: Oxcarbazepine-verapamil drug interactions in healthy volunteers. Epilepsia 1991; 32(Suppl 1):70-71
43. Zaccara G, Gangemi PF, Bandoni L, Menge GP, Monza GC: Evaluation of the influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Epilepsia 1991; 32(Suppl 1):71
44. Steinhoff BJ: Hyponatremic coma under oxcarbazepine therapy. Epilepsy Res 1992; 11:67-70
45. Malcolm R, Ballenger JC, Sturgis ET, Anton R: Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry 1989; 146:617-621
46. Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC: The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med 2002; 17:1-7
47. Stuppaeck CH, Pycha R, Whitworth AB, Oberbauer H, Fleischhacker WW: Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: A double-blind study. Alcohol Alcohol 1992; 27:153-158
48. Ries RK, Roy-Byrne PP, Ward NG, Neppe V, Cullison S: Carbamazepine treatment for benzodiazepine withdrawal. Am J Psychiatry 1989; 146:536-537
49. Schweizer E, Rickels K, Case WG, Greenblatt DJ: Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy: Effects on withdrawal severity and outcome. Arch Gen Psychiatry 1991; 48:448-452
50. Ballenger JC, Post RM: Kindling as a model for alcohol withdrawal syndromes. Br J Psychiatry 1978; 133:1-14
51. Schmutz M, Klebs K, Baltzer V: Inhibition or enhancement of kindling evolution by antiepileptics. J Neural Transm 1988; 72:245-257
52. Windhaber J, Maierhofer D, Dantendorfer K: Oxcarbazepine for panic disorder occurring after two grand mal seizures: A case report. J Clin Psychiatry 1997; 58:404-405
53. Emrich HM, Altmann H, Dose M, von Zerssen D: Therapeutic effects of GABA-ergic drugs in affective disorders: A preliminary report. Pharmacol Biochem Behav 1983; 19:369-372
54. Beijamini V, Skalisz LL, Joca SRL, Andreatini R: The effect of oxcarbazepine on behavioural despair and learned helplessness. Eur J Pharmacol 1998; 347:23-27
55. Huber TJ, Nickel V, Tröger M, Schneider U, Husstedt J, Emrich HM: A syndrome of psychosis following discontinuation of an estrogen-progestogen contraceptive and improvement following replacement: A case report. Neuropsychobiology 1999; 40:75-77
56. Dose M, Apelt S, Emrich HM: Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Res 1987; 22:303-310
57. Hernandez-Avila CA, Ortega-Soto HA, Jasso A, Hasfura-Buenaga CA, Kranzler HR: Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol. Psychiatr Serv 1998; 49:812-815
58. Mueller TI, Stout RL, Rudden S, Brown RA, Gordon A, Solomon DA, Recupero PR: A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res 1997; 21:86-92
59. Stuppaeck CH, Whitworth AB, Fleischhacker WW: Abuse potential of carbamazepine. J Nerv Ment Dis 1993; 181:519-520
60. Christensen J, Balslev T, Villadsen J, Heinsvig EM, Dam M, Poulsen JH: Removal of 10-Hydroxycarbazepine by plasmapheresis. Ther Drug Monit 2001; 23:374-379
61. Meldrum BS, Chapman AG: Basic mechanisms of Gabitril (tiagabine) and future potential developments. Epilepsia 1999; 40(Suppl 9):S2-S6
62. Borden LA: GABA transporter heterogeneity: Pharmacology and cellular localization. Neurochem Int 1996; 29:335-356
63. Schachter SC: A review of the antiepileptic drug tiagabine. Clin Neuropharmacol 1999; 22:312-317.
64. Schachter SC: Tiagabine. Epilepsia 1999; 40 (Suppl 5):S17-S22
65. Gustavson LE, Mengel HB: Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 1995; 36:605-611
66. Gustavson LE, Boellner SW, Granneman GR, Qian JX, Guenther HJ, el-Shourbagy T, Sommerville KW: A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology 1997; 48:1032-1037
67. Cato A III, Gustavson LE, Qian J, El-Shourbagy T, Kelly EA: Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine. Epilepsia 1998; 39:43-47
68. Gustavson LE, Cato A III, Boellner SW, Guoliang SC, Jiang XQ, Guenther HJ, Sommerville KW: Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin. Am J Ther 1998; 5:9-16
69. Gustavson LE, Sommerville KW, Boellner SW, Witt GF, Guenther HJ, Granneman GR: Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate. Am J Ther 1998; 5:73-79
70. Richens A, Marshall RW, Dirach J, Jansen JA, Snel S, Pedersen PC: Absence of interaction between tiagabine, a new antiepileptic drug, and the benzodiazepine triazolam. Drug Metabol Drug Interact 1998; 14:159-177
71. Wilbur K, Ensom MH: Pharmacokinetic drug interactions between oral contraceptives and second generation anticonvulsants. Clin Pharmacokinet 2000; 38:355-365
72. Samara EE, Gustavson LE, El-Shourbagy T, Locke C, Granneman GR, Sommerville KW: Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy. Epilepsia 1998; 39:868-873
73. Sveinbjornsdottir S, Sander JW, Patsalos PN, Upton D, Thompson PJ, Duncan JS: Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994; 3:29-35
74. Dodrill CB, Arnett JL, Sommerville KW, Shu V: Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997; 48:1025-1031
75. Dodrill CB, Arnett JL, Shu V, Pixton GC, Lenz GT, Sommerville KW: Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998; 39:33-42
76. Hogan RE, Bertrand ME, Deaton RL, Sommerville KW: Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. Epilepsy Res 2000; 41:23-28
77. Loiseau P: Review of controlled trials of gabatril (tiagabine): A clinician's viewpoint. Epilepsia 1999; 40 (Suppl 9):S14-S19
78. Booth BM, Blow FC: The kindling hypothesis: Further evidence from a U.S. national study of alcoholic men. Alcohol Alcohol 1993; 28:593-598
79. Brown ME, Anton RF, Malcolm R, Ballenger JC: Alcohol detoxification and withdrawal seizures: Clinical support for a kindling hypothesis. Biol Psychiatry 1998; 23:507-514
80. Gross MM, Rosendlatt SM, Lewis E, Chartoff S, Malenowski B: Acute alcoholic psychoses and related syndromes: Psychosocial and clinical characteristics and their implications. Br J Addict Alcohol Other Drugs 1972; 67:15-31
81. Lechtenberg R, Worner TM: Seizure risk with recurrent alcohol detoxification. Arch Neurol 1990; 47:535-538
82. Lechtenberg R, Worner TM: Relative kindling effect of detoxification and non-detoxification admissions in alcoholics. Alcohol Alcohol 1991; 26:221-225
83. Lechtenberg R, Worner TM: Total ethanol consumption as a seizure risk factor in alcoholics. Acta Neurol Scand 1992; 85:90-94
84. Shaw GK, Waller S, Latham CJ, Dunn G, Thomson AD: The detoxification of alcoholic in-patients and predictors of outcome. Alcohol Alcohol 1998; 33:291-303
85. Malcolm R, Roberts JS, Wang W, Myrick H, Anton RF: Multiple previous detoxifications are associated with less response and heavier drinking during an index outpatient detoxification. Alcohol 2000; 22:159-164
86. Worner TM: Relative kindling effect of readmissions in alcoholics. Alcohol Alcohol 1996; 31:375-380
87. Wojnar M, Bizon Z, Wasilewski D: Assessment of the role of kindling in the pathogenesis of alcohol withdrawal seizures and delirium tremens. Alcohol Clin Exp Res 1999; 23:204-208
88. Cleton A, Altorf BA, Voskuyl RA, Danhof M: Effect of amygdala kindling on the central nervous system effects of tiagabine: EEG effects versus brain GABA levels. Br J Pharmacol 2000; 130:1037-1044
89. Schmitt U, Hiemke C: Effects of GABA-transporter (GAT) inhibitors in rat behaviour in open-field and elevated plusmaze. Behav Pharmacol 1999; 10:131-137
90. Leppik IE: Tiagabine: The safety landscape. Epilepsia 1995; 36(Suppl 6) S10-S13
91. Zwanzger P, Baghai T, Schule C, Minov C, Padberg F, Moller HJ, Rupprecht R: Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry 2001; 62:656-657
92. Kastberg H, Jansen JA, Cole G, Wesnes K: Tiagabine: Absence of kinetic or dynamic interactions with ethanol. Drug Metabol Drug Interact 1998; 14:259-273
93. Tremont-Lukats IW, Megeff C, Backonja MM: Anticonvulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy. Drugs 2000; 60:1029-1052
94. Gerasimov MR, Schiffer WK, Brodie JD, Lennon IC, Taylor SJ, Dewey SL: Gamma-aminobutyric acid mimetic drugs differentially inhibit the dopamine reponse to cocaine. Eur J Pharmacol 2000; 395:129-135
95. Winhusen T, Somoza E, Goldsmith J, Dingal B, Harrer J, Mezinskis J, Coleman F, Elkashef A, Montgomery A, Leiderman D, Berger SP: A NIDA-sponsored clinical rapid efficacy screening trial (CREST) of tiagabine, sertraline, and donepezil. Drug Alcohol Depend 2001; 63(Suppl 1): S170-S171
96. Lancel M, Faulhaber J, Deisz RA: Effect of the GABA reuptake inhibitor tiagabine on sleep and EEG power spectra in the rat. Br J Pharmacol 1998; 123:1417-1477
97. Lands WE: Alcohol, slow wave sleep, and the somatotropic axis. Alcohol 1999; 18:109-122
98. Mathias S, Wetter TC, Steiger A, Lancel M: The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol Aging 2001; 22:247-253